SecBot SecBot
8-K ·Filed Oct 23, 2026

ACAD

ACADIA PHARMACEUTICALS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 16h ago SEC0001193125-26-430596
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor the next 8-K for the naming of a new Head of R&D appointment. The transition was pre-announced months ago and is not a surprise — no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Acadia Pharmaceuticals filed an 8-K confirming the departure of Elizabeth H.Z. Thompson, Ph.D., Executive Vice President and Head of Research and Development, effective October 23, 2026. Dr. Thompson had previously announced her planned retirement for personal reasons in April 2026. She will remain as a consultant through December 31, 2026, while the company searches for a replacement. This is a routine, pre-announced executive transition with no financial impact disclosed.

Key Facts

  • Elizabeth H.Z. Thompson, Ph.D., EVP and Head of R&D, departed as employee effective October 23, 2026
  • Departure was previously disclosed on May 1, 2026, as a planned retirement for personal reasons
  • Dr. Thompson will provide limited consulting services through December 31, 2026
  • Company is in the process of identifying a replacement for the Head of R&D role

Financial Impact

No financial figures disclosed in the filing

Risk Factors

  • Extended vacancy in the Head of R&D role could slow pipeline execution if replacement is not named promptly

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-430596
Document: 0001193125-26-430596-index-headers.html0001193125-26-430596
Document: 0001193125-26-430596-index.html0001193125-26-430596
Document: 0001193125-26-430596.txt0001193125-26-430596
11 reports for ACAD
Performance horizon
25% Hit rate @ T+20 1 of 4 directional calls Went positive at some point 2 of 4 best @ T+20▲ +5.01%May 6, 2026
Filters
Rows
Reports for ACAD — sortable, filterable
TypeNow
Oct 23, 2026
3d ago
8-K
NEUTRAL ★ 3/10
$19.73awaiting T+20—$19.75 (+0.10%)
Sep 24, 2026
4w ago
8-K
BULLISH ★ 6/10
$20.68 $19.73▼ −4.59%▼ −3.12%$19.75 (−4.50%)
Sep 11, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$27.52 $19.41▼ −29.47%▼ −31.73%$19.75 (−28.23%)
Aug 16, 2026
10w ago
Institutional Cluster
MIXED ★ 5/10
$29.01 $26.76▼ −7.76%▼ −5.78%$19.75 (−31.92%)
Aug 7, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$29.39 $27.58▼ −6.16%▼ −5.24%$19.75 (−32.80%)
Jun 11, 2026
19w ago
Institutional Cluster
BEARISH ★ 6/10
$21.39 $26.41▼ −23.47%▼ −21.58%$19.75 (+7.67%)
May 6, 2026
24w ago
8-K
BEARISH ★ 6/10
$22.56 $21.43▲ +5.01%▲ +8.14%$19.75 (+12.46%)
May 4, 2026
25w ago
Insider Cluster
NEUTRAL ★ 2/10
$22.19 $21.52▼ −3.02%▼ −8.66%$19.75 (−11.00%)
Mar 25, 2026
30w ago
Insider Cluster
NEUTRAL ★ 4/10
$22.01 $22.11▲ +0.45%▼ −7.41%$19.75 (−10.27%)
Mar 5, 2026
33w ago
8-K
NEUTRAL ★ 3/10
$22.40 $22.20▼ −0.89%▲ +2.90%$19.75 (−11.83%)
Showing 10 of 11

US Market Status

Market Open — Closes in 6h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 23, 2026